Pediatric Immunization

 
FDA Accepts Merck's BLA for Clesrovimab, an Investigational mAb Against RSV in Infants
December 17, 2024

Clesrovimab, if approved, would be the only immunization for both healthy and at risk infants using the same dose. FDA set A PDUFA date of June 2025.

Safety of Moderna’s mRNA RSV Vaccine for Infants Heads Dec 12 VRBPAC Meeting Agenda
December 11, 2024

Moderna paused clinical research on the pediatric shot indefinitely in September after reports in July of severe adverse reactions in infants aged 5 to 8 months.

HPV Vaccination Rates, Clinician Recommendations Lag at Public Health Care Facilities
August 02, 2024

HPV series initiation and completion was lower among adolescents seen at public vs private care settings and so was clinician guidance on vaccination in a new study.

States with Higher COVID-19 Vaccination Rates Saw Reduction in Pediatric Asthma Prevalence
July 09, 2024

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

Nirsevimab for RSV Reduces Infant Hospitalizations by 82% in Real-World Study
May 02, 2024

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA
April 17, 2024

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

Measles and the Collective American Memory: 3 Questions
March 18, 2024

Measles cases are edging up in the US again as MMR vaccination rates continue to decline. Have parents forgotten the Ohio outbreak of 2022? Have you? Find out, here.

Nirsevimab Effective Against RSV Hospitalization among Infants: Daily Dose
March 18, 2024

Your daily dose of the clinical news you may have missed.

Nirsevimab 90% Effective Against RSV Hospitalization among Infants, According to New CDC Data
March 11, 2024

Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.

Of Vaccine Efficacy and COVID-19 Variants: 4 Questions
February 16, 2024

Just when the new monovalent COVID-19 vaccines were available in Sept 2023, a new variant emerged. Did the CDC get it right? What do you know about the monovalent VE?